Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness Through Virus-Host...

— —

Tibor Bakacs, MD, PhD, DSc (Chief Scientific Officer of HepC Inc and Pret Therapeutics Ltd.; Consultant, Department of Probability, Alfred Renyi Institute of Mathematics, Hungary)

Leveraging Viruses for the Treatment of Viral Diseases and Cancer

Improving Host Fitness Through Virus-Host Genetic Combinations

Tibor Bakacs, MD, PhD, DSc (Chief Scientific Officer of HepC Inc and Pret Therapeutics Ltd.; Consultant, Department of Probability, Alfred Renyi Institute of Mathematics, Hungary)

$318.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
21 November 2025

Medical microbiology & virology; Virology (non-medical)

Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge.

More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.

Edited by: Tibor Bakacs MD PhD DSc (Chief Scientific Officer of HepC Inc and Pret Therapeutics Ltd.; Consultant Department of Probability Alfred Renyi Institute of Mathematics Hungary)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 229mm, Width: 152mm,
Weight: 450g
ISBN: 9780443291647
ISBN 10: 0443291640
Pages: 214
Publication Date: 21 November 2025
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

Dr. Tibor Bakacs has 40 years of experience in scientific research. His current interests are (i) viral superinfection treatment (SIT) of hepatitis B and C virus infected patients with unmet needs; (ii) oncolytic Newcastle Disease virus (NDV) therapy of advanced cancer; (iii) therapeutic application of autoimmune T-cells, which are induced by an off-label low-dose immune checkpoint blockade in advanced cancer. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He spent longer periods abroad, at the Karolinska Institute in Stockholm, Sweden, Christie Hospital in Manchester, UK and the National Cancer Institute (NCI/NIH) in the USA. Currently, he is the Chief Scientific Officer of Superinfection, Pret Therapeutics Ltd, and Lodoco Clinical Ltd. He is also a consultant at the Department of Probability, Alfred Renyi Institute of Mathematics. Dr. Bakacs authored 75 scientific papers and has two patents.